| Summary: | Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular [CV] disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated that there were 3.4 million people (9.3% of the population) with diabetes in 2015, and by 2025 this number will have increased to five million people (12.1%). The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin (ERT) 5 mg and 15 mg tablets to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance (as monotherapy); or in combination with metformin, or metformin and sitagliptin, when these therapies, along with diet and exercise, do not provide adequate glycemic control. This review was conducted in tandem with an evaluation of the ERT/metformin fixed-dose combination product, Segluromet
|
|---|